We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Accuracy of Point-of-Care Tests for Syphilis Analyzed

By LabMedica International staff writers
Posted on 12 Mar 2013
Syphilis is on the rise worldwide and there is an urgent need for reliable and rapid screening, particularly for people who live in areas where access to health care is limited. More...


A major change in approach to syphilis testing has been called for which recommends replacing first-line laboratory tests with point-of-care tests (POC) tests globally, especially in resource-limited settings.

An international team, led by scientists at McGill University Health Center (Montreal, QC, Canada) has demonstrated that rapid POC tests for syphilis are as accurate as conventional laboratory tests. Currently, syphilis is screened using conventional laboratory-based tests that can take up to three weeks to deliver results. These tests require chemical agents, trained staff, and a continuous supply of electricity, which are not readily available in some parts of the world. Rapid and POC tests can be performed on a simple finger stick sample one patient at a time, and the results communicated to the patient within 20 minutes, saving time and helping doctors order confirmatory tests and rapidly flagging patients who need treatment.

The team identified 18 rapid and POC tests in global use in a meta-analysis. The vast majority were immunochromatographic strip (ICS) based assays with most tests being Determine (Abbott Diagnostics; Maidenhead, UK) at 29% (38/131); SD Biolines (Standard Diagnostics; Seoul, South Korea) at 18% (23/131); VisiTect (Omega Diagnostics; Alva, UK) at 16% (21/131); and Syphicheck (Qualpro; Goa, India) at 15% (19/131). In whole blood sample, using a Treponema pallidum (TP) specific reference standard, under the imperfect reference standard assumption, sensitivity and specificity estimates for Determine was 86.3% and 95.9%; for SD Bioline was 84.5% and 98.0%; for Syphicheck was 74.5% and 99.6%; and for VisiTect was 74.3% and 99.4%.

Nitika Pant Pai, MD, MPH, PhD, a lead author of the study said, “Our study has major worldwide implications for populations living in rural areas with limited access to healthcare. These tests offer the potential to expedite first line screening in settings where people have no access to a primary care physician or where laboratories take more than a week to deliver results." The study was published on February 26, 2013, in the journal Public Library of Science ONE.

Related Links:

McGill University Health Center
Abbott Diagnostics
Standard Diagnostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Drug Testing Assays
Atellica DT 250 Analyzer
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Age-Based Genetic Testing May Miss Most Inherited Cancer Risk Variants

Inherited cancer risk can influence diagnosis, treatment planning, and family screening, yet current testing practices often depend on a patient’s age at diagnosis. Many patients undergo germline genetic... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.